Previous 10 | Next 10 |
KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ...
Karyopharm Therapeutics (KPTI) shares climbs 5% in premarket after the European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending the conditional approval for multiple myeloma treatment, Nexpovio (selinexor) in combination with dexam...
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma -- European Commission Decision Anticipated by April 2021 -- PR Newswire NEWTON, Mass. , Jan. 29, 2021 /PRNewswire/ -- ...
Our Roundtable series continues with a focus on biotech and healthcare investing. Apart from COVID-19 and vaccines, opportunities abound. The series will end this week with growth/tech investing and macro and technical analysis. For further details see: 2021 Roundtable: ...
Karyopharm Therapeutics ([[KPTI]] -8.0%) expects total Q4 revenues to be between $35M-36M and between $108M-109M for the FY of 2020, including net product sales for XPOVIO.Additionally, company expects net product sales of XPOVIO to be between $20M-20.5M during Q4 and between $76M- -76.5...
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update -- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Ye...
Antengene has submitted an Investigational New Drug ((IND)) application for ATG-010 (selinexor, XPOVIO) being co-developed by Karyopharm Therapeutics (KPTI) to the National Medical Products Administration ((NMPA)) in the treatment of Endometrial Cancer.The Phase 3, d...
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today...
Antengene submits a New Drug Application ((NDA)) in South Korea for ATG-010 (selinexor, XPOVIO) in combination with low dose dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (rrMM) and for ATG-010 as monotherapy for treatment of relaps...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...